Swiss National Bank Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Swiss National Bank lessened its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 286,600 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Swiss National Bank’s holdings in TG Therapeutics were worth $6,704,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. NBC Securities Inc. boosted its holdings in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the period. Quarry LP boosted its position in TG Therapeutics by 9.1% during the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 503 shares in the last quarter. Private Advisor Group LLC lifted its stake in shares of TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after purchasing an additional 542 shares during the last quarter. Blue Trust Inc. boosted its position in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. Finally, KBC Group NV raised its holdings in TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,092 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by insiders.

TG Therapeutics Stock Down 1.0 %

Shares of TGTX stock opened at $34.26 on Wednesday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.30 and a twelve month high of $36.84. The stock has a 50 day moving average of $25.81 and a 200 day moving average of $21.83. The stock has a market cap of $5.33 billion, a P/E ratio of -342.60 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.73 EPS. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. B. Riley raised their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.